Keytruda (pembrolizumab) / Merck (MSD) - LARVOL DELTA

Successful Use of Ruxolitinib for Steroid-Refractory Immune Checkpoint Inhibitor-Associated Myocarditis. (PubMed, JACC Case Rep) - "ICI-associated myocarditis can present with ventricular arrhythmia and heart failure. Ruxolitinib may be considered in steroid-refractory cases."

Checkpoint inhibition • IO biomarker • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Ventricular Tachycardia

GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER (IGCS 2025) - " Adults with primary stage III (measurable) or stage IV or recurrent (measurable or nonmeasurable) pMMR EC per RECISTv1.1 by investigator and no prior systemic therapy (except 1 prior line of platinum-based [neo]adjuvant chemotherapy in the curative-intent setting) will receive 6 cycles of induction treatment with pembrolizumab, carboplatin, and paclitaxel (≤2 additional cycles of pembrolizumab allowed). Participants with PD confirmed by BICR during or after induction (ie, ineligible for maintenance therapy) may receive randomized subsequent treatment with sac-TMT plus pembrolizumab or sac-TMT alone. Current Status & Future Directions: Enrollment begins in May 2025."

Clinical • Mismatch repair • P3 data • pMMR • Endometrial Cancer • Oncology • Solid Tumor • TACSTD2

COMPLETE PATHOLOGICAL RESPONSE TO NEOADJUVANT IMMUNOTHERAPY IN A RESISTANT LOCALLY ADVANCED ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA CASE : CASE REPORT (IGCS 2025) - "She received neoadjuvant carboplatin-paclitaxel, followed by pembrolizumab and lenvatinib. Immunotherapy with pembrolizumab and lenvatinib achieved complete pathological response in chemotherapy-resistant dMMR endometrial cancer, offering a promising, well-tolerated option when surgery is initially not feasible."

Case report • Clinical • Metastases • Endometrial Cancer • Oncology • Solid Tumor

DIAGNOSIS AND MANAGEMENT OF PLACENTAL SITE TROPHOBLASTIC TUMOR IN LOW RESOURCE SETTING (IGCS 2025) - "Subsequently treated with Etoposide and Cisplatin for 6 cycles, then retreated with Pembrolizumab for 5 cycles. Placental site trophoblastic tumor is a rare and potentially curable condition if diagnosed early. Histopathology is the mainstay in the diagnosis of placental site trophoblastic tumor as there are no classical radiological features that will assist in preoperative diagnosis."

Gestational Trophoblastic Neoplasia • Oncology

SURVIVING VULVAR MELANOMA: A GLIMPSE OF LIGHT IN THE DARKNESS (IGCS 2025) - "Our working diagnosis was Malignant Melanoma, Vulva, Stage IIIC (T4bN1cM0); Breslow's Depth V; Clark's level IV; s/p Cystourethroscopy, Sentinel Lymph node mapping followed by Bilateral Inguinofemoral Lymph Node Dissection, Wide Local Excision, Tumor Recurrence (Vulva); s/p Dacarbazine 800mg/m2 V s/p IMRT (55.20 Gy 06/29/22-08/02/22) Tumor Persistence; s/p Pembrolizumab I (09/13/22) Conclusion/Implications: The management of patients who develop recurrence must be individualized and that radiation therapy may only have a room for palliative intent. Systemic chemotherapy agents have a modest response but with the longest established monotherapy but still with over all poor survival rates. Novel immunotherapeutic and targeted agents have been reported to improve survival in melanoma and should be considered but still clinical trials are encouraged to be able to established their effectiveness."

Melanoma • Oncology • Solid Tumor • Vulvar Cancer

PEMBROLIZUMAB IN CHEMO-RESISTANT GESTATIONAL TROPHOBLASTIC NEOPLASIA (IGCS 2025) - "In this study, 2/6 patients continue to have complete remission after Pembrolizumab. One patient went into CR later. Another patient with SD after 2 cycles, eventually progressed due to unaffordability."

Gestational Trophoblastic Neoplasia • Oncology • PD-L1

SERUM SQUAMOUS CELL CARCINOMA ANTIGEN TO ESTIMATE STAGE-BASED RISK OF LYMPH NODE INVOLVEMENT IN CERVICAL CANCER (IGCS 2025) - "CRT included EBRT and brachytherapy with cisplatin (no pembrolizumab). 453 patients were identified in cohort 1, 230 from cohort 2. LNM rate was 57.6% in cohort 1, unknown in cohort 2. SCCA was significantly different in patients with LNM versus none."

Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

NEO ADJUVANT CHEMOIMMUNOTHERAPY FOLLOWED BY CHEMORADIATION AND MAINTENANCE IMMUNOTHERAPY FOR HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER: A PHASE 3, RANDOMISED, OPEN LABEL STUDY (IGCS 2025) - "Introduction: Patients of Stage III and IVA carcinoma cervix patients are at high risk of relapse and have frequent treatment failure with current standard of care that includes chemoradiation with or without pembrolizumab...Trial Design: This will be a phase 3, randomised, open label, study comparing addition of low dose nivolumab to neoadjuvant chemotherapy followed by CCRT and maintenance nivolumab to neoadjuvant chemotherapy and CCRT alone... In this study, we aim to use combination of chemotherapy and lower dose immunotherapy prior to definitive chemoradiation and then continued as maintenance in a subset of patients who are at high risk of relapse. Lower doses of immunotherapy will keep the overall cost of treatment under check while improving the efficacy."

Clinical • Metastases • P3 data • Cervical Cancer • Oncology • Solid Tumor

LOW NEUTROPHIL-TO-LYMPHOCYTE RATIO IS ASSOCIATED WITH IMPROVED PROGRESSION FREE SURVIVAL IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: AN ANCILLARY ANALYSIS OF NRG-GY018 (IGCS 2025) - "NLR was calculated for 805 (98.3%) patients. High NLR (n=161) was associated with performance status >0, prior radiation, and absence of prior surgery. High NLR was associated with decreased PFS regardless of treatment arm [figure 1] and the association held when adjusting for the covariates above."

Clinical • Metastases • Endometrial Cancer • Oncology • Solid Tumor

REAL-WORLD CLINICAL OUTCOMES OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB FOR THE TREATMENT OF PATIENTS WITH NON-MSI-H/PMMR RECURRENT OR ADVANCED ENDOMETRIAL CANCER IN THE UNITED STATES (IGCS 2025) - "Introduction: The KEYNOTE-775/Study-309 trial demonstrated statistically significantly improved outcomes with lenvatinib plus pembrolizumab (LEN+PEM) vs doxorubicin/paclitaxel chemotherapy (CT) in advanced/recurrent endometrial cancer (aEC) patients following previous systemic therapy (FPST). In the LEN+PEM (n=97) and CT (n=107) cohorts, median age was 57.7 and 57.1 years, 61.9% and 60.7% patients were White, 83.5% and 67.3% had endometrioid carcinoma, 58.8% and 43.0% had PS 0/1, respectively. The sIPTW-adjusted analysis favored LEN+PEM vs CT with a HR (95%CI) of 0.59 (0.38-0.91) for rwPFS (median: 13.1 [9.0-15.4] vs 8.4 [5.8-11.1] months), 0.69 (0.45-1.05) for OS (median: 19.6 [16.9-26.3] vs 13.5 [11.9-17.6] months), and OR of 2.40 (1.31-4.40) for rwORR (46.3% vs 26.1%). The multivariable Cox regression findings were consistent with the sIPTW-adjusted analysis."

Clinical • Clinical data • Combination therapy • Metastases • MSI-H • Real-world • Real-world evidence • Endometrial Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

REAL-WORLD EFFECTIVENESS OF FIRST-LINE PEMBROLIZUMAB MONOTHERAPY AMONG MSI-H/DMMR ADVANCED OR RECURRENT ENDOMETRIAL CANCER PATIENTS IN THE US (IGCS 2025) - "The KEYNOTE-C93 trial evaluates the efficacy of PEM vs. carboplatin + paclitaxel (C+P) in advanced and recurrent endometrial cancer (aEC) in 1L settings among patients with MSI-H/dMMR tumors. Of 221 eligible patients with MSI-H/dMMR tumors, 78 (35%) initiated 1L PEM. For patients treated with PEM or C+P, median age at aEC diagnosis was 70 and 65 years, proportion white was 56% and 68%, and proportion recurrent was 77% and 47%, respectively. Overall, median (95% confidence interval) rwToT and rwTTNT was 9.0 (5.1-14.5) (Table 1) and 16.6 (8.3-47.4) months for PEM (Figure 1a) and 3.5 (3.4-3.5) and 5.8 months (5.4-6.7) for C+P in all patients."

Clinical • Metastases • Monotherapy • MSI-H • Real-world • Real-world effectiveness • Real-world evidence • Endometrial Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY (IGCS 2025) - P3 | "Introduction: In the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study (NCT04634877) in participants with high-risk endometrial cancer (EC), addition of pembrolizumab to adjuvant carboplatin + paclitaxel ± radiotherapy (CTx±RT) did not improve DFS (primary endpoint) at interim analysis 3 (IA3) in the overall population. Of 1095 randomized participants, HRQoL analyses included 1083 and 280 participants in the overall and dMMR populations, respectively. There were no meaningful differences between treatment groups for change in HRQoL scores from baseline to week 45 in the overall or dMMR populations (Table 1). In both treatment arms, QLQ-C30 GHS/QoL scores decreased after initiation of CTx±RT, with scores trending back to baseline after completion of CTx±RT (Figure 1).Conclusion/Implications: There were no meaningful differences between treatment groups in HRQoL in the overall or dMMR populations."

Clinical • HEOR • P3 data • Endometrial Cancer • Oncology • Solid Tumor

FIRST-LINE LENVATINIB + PEMBROLIZUMAB VERSUS CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER: ADDITIONAL 1-YEAR FOLLOW-UP RESULTS FROM ENGOT-EN9/LEAP-001 (IGCS 2025) - P3 | "Participants were randomized 1:1 to oral L 20mg QD+intravenous P 200mg Q3W or CT (paclitaxel+carboplatin) until PD/unacceptable toxicity. 842 participants were randomized. At data cutoff (5-February-2025), overall median follow-up was 54.5 (range, 46.5‒69.0) months. Results are below."

Clinical • Metastases • Endometrial Cancer • Oncology • Solid Tumor

LENVATINIB PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775 AND ENGOT-EN9/LEAP-001 POST-(NEO)ADJUVANT THERAPY OUTCOMES (IGCS 2025) - P3 | "Participants were randomized 1:1 to L 20mg QD + P 200mg Q3W or chemotherapy (doxorubicin or paclitaxel in study 309; paclitaxel+carboplatin in LEAP-001). Median (range) follow-up in participants with prior (neo)adjuvant chemotherapy only was 68.8 (61.0–79.1) months in Study 309 (data cutoff: February 26, 2025) and 50.7 (46.6–63.7) months in LEAP-001 (data cutoff: February 5, 2025). Results are in Tables 1–2. Additional results will be included in the presentation (efficacy by MMR status, histology, PFI etc)."

Clinical • Metastases • Endometrial Cancer • Oncology • Solid Tumor

PEMBROLIZUMAB PLUS CONCURRENT CHEMORADIOTHERAPY FOR HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER: POST HOC SUBGROUP ANALYSES FROM THE PHASE 3 ENGOT-CX11/GOG-3047/KEYNOTE-A18 STUDY (IGCS 2025) - P3 | "CCRT was 5 cycles (optional 6th dose) of cisplatin 40 mg/m2 Q1W+external beam radiotherapy then brachytherapy. PFS and OS results are shown in Table 1 and 2, respectively.Conclusion/Implications: In this post hoc analysis, pembrolizumab+CCRT improved PFS and OS vs placebo+CCRT in participants with FIGO 2014 stage III‒IVA LACC, regardless of pelvic/para-aortic LN involvement. PFS benefit was also seen with pembrolizumab+CCRT in participants with stage IB2‒IIB disease with target lesions >5 cm."

Metastases • P3 data • Retrospective data • Cervical Cancer • Oncology • Solid Tumor

PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826 (IGCS 2025) - P3 | "All participants received chemotherapy (paclitaxel plus carboplatin or cisplatin); bevacizumab use was per investigator's discretion. 617 participants were randomized. At data cutoff (June 4, 2024), after median follow-up of 59.1 (range, 52.1–66.5) months, pembrolizumab maintained an OS and PFS benefit versus placebo in all populations (Table). Grade ≥3 treatment-related AEs occurred in 69.4% of participants in the pembrolizumab group and 65.4% in the placebo group, and immune-mediated AEs/infusion reactions in 43.6% and 29.8%, respectively."

Metastases • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Late-Breaking Abstract: PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY (IGCS 2025) - No abstract available

Clinical • Late-breaking abstract • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

LENVATINIB PLUS PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PARTICIPANTS WITH ADVANCED ENDOMETRIAL CANCER: 5-YEAR OUTCOMES FROM STUDY 309/KEYNOTE-775 (IGCS 2025) - P3 | "Participants were randomized 1:1 to L 20mg orally QD plus P 200mg IV Q3W or TPC (doxorubicin or paclitaxel). 827 participants were randomized. At data cutoff (26-February-2025), overall median follow-up was 68.8 (range, 60.8‒80.0) months; 139 participants were alive (L+P, 86; TPC, 53), and all had ended their treatment. Results are in Tables 1–2."

Metastases • Endometrial Cancer • Oncology • Solid Tumor

A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER (IGCS 2025) - "Patients received a median of 2 prior therapies (range:1-4) and 50% had failed pembrolizumab/dostarlimab. Fifty patients were enrolled/evaluable, including 21 (50 screened) and 29 (34 screened) in stages 1/2, respectively. Eighty-four percent (n=42) harbored serous carcinoma, carcinosarcoma, or grade 3 endometrioid tumors (Table 1). Median follow-up was 10.3 months (range:2.4-59.5)."

Clinical • IO biomarker • P2 data • Carcinosarcoma • Endometrial Cancer • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • TACSTD2

KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8% (Merck (MSD) Press Release)

Sales • Bladder Cancer • Cervical Cancer • Cholangiocarcinoma • Colorectal Cancer • Cutaneous Melanoma • Endometrial Cancer • Esophageal Squamous Cell Carcinoma • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • HER2 Negative Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Merkel Cell Carcinoma • Microsatellite Instability • Pancreatic Cancer • Primary Mediastinal Large B-Cell Lymphoma • Renal Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Nous-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results (ESMO 2025) - P1/2 | "Among those, 86% remained in SD and 14% had PR, the PR demonstrating induction of a strong and polytopic T effector memory phenotype cell immune response corresponding to clinical response. Conclusions Overall, these data demonstrated a 15% ORR, 70% DCR and mPFS of 6.4 months in αPD-1 refractory MSI-H mCRC patients treated with Nous209 plus pembrolizumab."

Metastases • MSI-H • P2 data • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Effectiveness of maintenance therapy with pembrolizumab vs pemetrexed and pembrolizumab in advanced non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315) (ESMO 2025) - "Legal entity responsible for the study AIO-Studien-gGmbH, Kuno-Fischer-Str. 8, 14057 Berlin, Germany."

Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • ROS1

LENVATINIB-INDUCED TUMOR CAVITATION COMPLICATED BY PNEUMOTHORAX: A RARE AND LIFE-THREATENING PHENOMENON (CHEST 2025) - "CASE PRESENTATION: A 67-year-old female with stage IV FIGO 3C1 metastatic endometrial cancer was started on systemic chemotherapy with pembrolizumab, carboplatin, and paclitaxel. This case emphasizes the need to remain vigilant for pneumothorax secondary to ruptured cavitary lung lesions in patients on lenvatinib therapy. Although rare, this syndrome can prove fatal if not recognized. Clinicians should review imaging carefully in patients with malignant pulmonary nodules for the development of cavitary changes that may herald a pneumothorax."

Endometrial Cancer • Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thyroid Gland Carcinoma

Immune Checkpoint Inhibitor - Associated Renal Tubular Acidosis and Nephrogenic Diabetes Insipidus: A Case Report. (PubMed, Case Rep Nephrol Dial) - "Management involved withholding pembrolizumab, initiating high-dose prednisone therapy, and correcting hypokalemia and metabolic acidosis. This case emphasizes the importance of recognizing renal complications in patients undergoing treatment with immune checkpoint inhibitors. Awareness of potential adverse effects such as RTA and NDI is crucial for prompt identification and management to prevent lasting damage."

Checkpoint inhibition • Journal • Acute Kidney Injury • Melanoma • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Oncology • Pain • Renal Disease • Solid Tumor

Final Results of the FAK-PD1 Phase I/IIA Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Tumours (ESMO-IO 2025) - No abstract available

Clinical • Metastases • P1/2 data • Oncology • Solid Tumor